Ibrutinib Imbruvica

Approved by the FDA on 29 January 2015, Ibrutinib (Imbruvica®) is used for a lymphoma type called Waldenström macroglobulinemia in affected patients. It also received approval in 2013 for mantle cell lymphoma. It acts on cancer cells at the level of tyrosine kinase receptors. This prevents further cancer cell growth, proliferation and spread to distant tissues.
Its most common side effects are decreased platelets (cells that stop bleeding), diarrhea, anemia, fatigue, pain and swelling.
Was this article helpful?
Your feedback helps us improve our content.



Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.